Tvardi Therapeutics (TVRD) Net Income towards Common Stockholders: 2013-2017
Historic Net Income towards Common Stockholders for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$12.4 million.
- Tvardi Therapeutics' Net Income towards Common Stockholders fell 7.81% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.01%. This contributed to the annual value of -$57.3 million for FY2016, which is 132.00% down from last year.
- Latest data reveals that Tvardi Therapeutics reported Net Income towards Common Stockholders of -$12.4 million as of Q3 2017, which was down 33.81% from -$9.3 million recorded in Q2 2017.
- Tvardi Therapeutics' 5-year Net Income towards Common Stockholders high stood at $5.4 million for Q2 2013, and its period low was -$22.2 million during Q1 2017.
- For the 3-year period, Tvardi Therapeutics' Net Income towards Common Stockholders averaged around -$11.4 million, with its median value being -$10.7 million (2016).
- In the last 5 years, Tvardi Therapeutics' Net Income towards Common Stockholders tumbled by 167.20% in 2014 and then rose by 28.87% in 2017.
- Quarterly analysis of 5 years shows Tvardi Therapeutics' Net Income towards Common Stockholders stood at -$2.1 million in 2013, then crashed by 99.33% to -$4.2 million in 2014, then slumped by 128.43% to -$9.5 million in 2015, then crashed by 130.56% to -$22.0 million in 2016, then dropped by 7.81% to -$12.4 million in 2017.
- Its Net Income towards Common Stockholders stands at -$12.4 million for Q3 2017, versus -$9.3 million for Q2 2017 and -$22.2 million for Q1 2017.